Search Results

PROMETHEUS Data Compare Use of Prasugrel and Clopidogrel in Real-World Practice

May 8, 2015—Results of the PROMETHEUS study were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 scientific sessions being held May 6–9 in San Diego, California.

TWILIGHT Will Study Ticagrelor-Alone Therapy for Stent Patients

August 21, 2015—The Icahn School of Medicine at Mount Sinai in New York, New York, announced the launch of the international TWILIGHT clinical trial to test the safety and effectiveness of treating coronary drug-eluting stent patients with the anticlotting medication ticagrelor alone, instead of combining it with aspirin for dual-antiplatelet therapy (DAPT), which is the current standard of care.

TWILIGHT Substudy Compares Safety of Bioabsorbable Polymer and Durable Polymer DES in High-Risk Patients Undergoing PCI

May 14, 2020—The Society for Cardiovascular Angiography and Interventions (SCAI) announced that subgroup findings from the TWILIGHT trial sought to reveal whether drug-eluting stents (DESs) coated with a bioabsorbable polymer (BP) provided a safety advantage without compromising efficacy compared with durable polymer (DP) formulations.

PROMETHEUS Compares Women and Men Treated With PCI for ACS

May 6, 2016—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the presentation of the PROMETHEUS study, showing that women younger than 55 years of age who undergo percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) are more likely to experience 1-year adverse cardiovascular events due to risk factors such as diabetes and chronic kidney disease. However, they are less likely than men to receive the more-potent antiplatelet therapy prasugrel as opposed to clopidogrel.

BRAVO-3 Trial Shows Increased Risk of Early Stroke With New-Onset Atrial Fibrillation After TAVR

May 11, 2017—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the presentation of data from the BRAVO-3 randomized trial showing that more than one-third of patients undergoing transcatheter aortic valve replacement (TAVR) had atrial fibrillation (AF) either at baseline or new-onset AF within 30 days after TAVR.